Aripiprazole in Youth with Intellectual Disabilities: A Retrospective Chart Study

Autor/inn/en	Reurts, Eva Enneke; Troost, Pieter W.; Dinnissen, Mariken; Reijnen, Sam; Hoekstra, Pieter J.; Popma, Arne
Titel	Aripiprazole in Youth with Intellectual Disabilities: A Retrospective Chart Study
Quelle	In: Journal of Intellectual Disabilities, 25 (2021) 4, S.449-457 (9 Seiten) PDF als Volltext Verfügbarkeit
Zusatzinformation	ORCID (Reurts, Eva Enneke)
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	1744-6295
DOI	10.1177/1744629520905175
Schlagwörter	Mild Intellectual Disability; Drug Therapy; Outcomes of Treatment; Foreign Countries; Age Differences; Gender Differences; Intelligence Quotient; Program Effectiveness; Behavior Modification; Symptoms (Individual Disorders); Comorbidity; Autism; Pervasive Developmental Disorders; Attention Deficit Hyperactivity Disorder; Children; Adolescents; Young Adults; Behavior Problems; Netherlands; Wechsler Intelligence Scale for Children + Suchen Sie Ihr Suchwort? Ausland; Age; Difference; Age difference; Altersunterschied; Geschlechterkonflikt; Intelligenzquotient; Behaviour modification; Verhaltensänderung; Psychiatrische Symptomatik; Autismus; Child; Kind; Kinder; Adolescent; Adolescence; Adoleszenz; Jugend; Jugendalter; Jugendlicher; Young adult; Junger Erwachsener; Niederlande
Abstract	A retrospective chart study of patients on open-label aripiprazole treatment was conducted in the Netherlands to add to the knowledge of aripiprazole in children and young adults with mild and borderline intellectual disabilities (IDs). Fifty-three youths, mean age 14.7 ± 3.4 years and mean IQ 64.5 ±13.8, were included. Treatment responders were defined as "much improved" or "very much improved" based on the Clinical Global Impression-Improvement scale. For 83% of the patients, disruptive behavior was the main target symptom. The overall response rate was 30% after 1-4 weeks and 69% after 5-8 weeks. The 5-8 weeks responders showed a response rate of 64% at 22-26 weeks. Mild adverse events were observed in 53% of the patients of which fatigue and weight gain were the most common. Seven patients (13.2%) discontinued because of adverse events. In 53 children and young adults with mild and borderline IDs, aripiprazole was effective in both the short and the long term. No serious adverse events were observed. (As Provided).
Anmerkungen	SAGE Publications. 2455 Teller Road, Thousand Oaks, CA 91320. Tel: 800-818-7243; Tel: 805-499-9774; Fax: 800-583-2665; e-mail: journals@sagepub.com; Web site: http://sagepub.com
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2024/1/01